Efficacy and Safety of Lactobacillus Plantarum C29-Fermented Soybean (DW2009) in Individuals with Mild Cognitive Impairment: A 12-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- 주제(키워드) Mild cognitive impairment , Lactobacillus plantarum C29-fermented soybean (DW2009) , Cognitive impairment , Brain-derived neurotrophic factor
- 주제(기타) Nutrition & Dietetics
- 설명문(일반) [Hwang, Yun-Ha; Jeong, Doc-Gyun; Na, Kyu-Heum] DONGWHA Pharm Res Inst, 35-71 Topsil Ro, Yongin 17084, South Korea; [Park, Shinwon; Ha, Eunji; Kim, Myeongju; Hong, Gahae; Kim, Jungyoon] Ewha Womans Univ, Ewha Brain Inst, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Park, Shinwon; Ha, Eunji; Kim, Myeongju; Hong, Gahae; Kim, Jungyoon] Ewha Womans Univ, Dept Brain & Cognit Sci, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Paik, Jong-Woo; Lee, Sang-Min] Kyung Hee Univ, Dept Psychiat, Coll Med, 26 Kyungheedae Ro, Seoul 02447, South Korea; [Chae, Soo-Wan; Park, Soo-Hyun; Jung, Su-Jin] Chonbuk Natl Univ Hosp, Clin Trial Ctr Funct Foods, 20 Geonjiro, Jeonju Si 54907, South Korea; [Kim, Dong-Hyun] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea; [Chung, Young-Chul] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst, 20 Geonjiro, Jeonju Si 54907, South Korea
- 관리정보기술 faculty
- 등재 SCIE, SCOPUS
- OA유형 Green Published, gold, Green Submitted
- 발행기관 MDPI
- 발행년도 2019
- URI http://www.dcollection.net/handler/ewha/000000160376
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/nu11020305
- PubMed https://pubmed.ncbi.nlm.nih.gov/30717153
초록/요약
Early intervention using dietary supplements may be effective in alleviating cognitive impairment among individuals with mild cognitive impairment (MCI). This study investigated the efficacy and safety of Lactobacillus plantarum C29-fermented soybean (DW2009) as a nutritional supplement for cognitive enhancement. One hundred individuals with MCI were randomly assigned to take DW2009 (800 mg/day, n = 50) or placebo (800 mg/day, n = 50) for 12 weeks. The primary outcome measure was change in the composite score of cognitive functions related to memory and attention, measured by computerized neurocognitive function tests. Associations between changes in serum brain-derived neurotrophic factor (BDNF) levels and cognitive performance for each treatment group were evaluated. Compared to the placebo group, the DW2009 group showed greater improvements in the combined cognitive functions (z = 2.36, p for interaction = 0.02), especially in the attention domain (z = 2.34, p for interaction = 0.02). Cognitive improvement was associated with increased serum BDNF levels after consumption of DW2009 (t = 2.83, p = 0.007). The results of this clinical trial suggest that DW2009 can be safely administered to enhance cognitive function in individuals with MCI. Increased serum BDNF levels after administering DW2009 may provide preliminary insight into the underlying effects of cognitive improvement, which suggests the importance of the gut-brain axis in ameliorating cognitive deficits in MCI.
more